European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopenic purpura published by the International Society on Thrombosis and Haemostasis.

---

Atıf İçin Kopyala

Eller K., Knoebl P., Bakkaloglu S. A., Menne J. J., Brinkkoetter P. T., Grandt L., ...Daha Fazla

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, cilt.37, ss.1229-1234, 2022 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 37
• Basım Tarihi: 2022
• Doi Numarası: 10.1093/ndt/gfac034
• Dergi Adı: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
• Sayfa Sayıları: ss.1229-1234
• Anahtar Kelimeler: AKI, guidelines, plasma exchange, systematic review, thrombotic microangiopathy, RITUXIMAB, PROPHYLAXIS, CONSENSUS, REMISSION
• Gazi Üniversitesi Adresli: Evet

Özet

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that is caused by severe ADAMTS-13 deficiency. Immune-mediated TTP develops due to autoantibodies against ADAMTS-13, whereas congenital TTP is caused by mutations in the ADAMTS13 gene. Diagnostic possibilities and treatment options in TTP have emerged in recent years, which prompted the International Society on Thrombosis and Haemostasis (ISTH) to publish clinical practice guidelines for the diagnosis and treatment of TTP in 2020. In this article, the European Renal Best Practice Working Group endorsed the ISTH guidelines and emphasizes a number of considerations, including the importance of rapid ADAMTS-13 activity testing, the use of rituximab and anti-von Willebrand factor therapies such as caplacizumab, that enhance the clinical applicability of the guidelines in Europe.